Treatment of inflammatory bowel diseases with anti-IP-10 antibodies
View Patent ↗The present invention is directed to high affinity anti-human IP-10 antibodies or antigen-binding fragments of these antibodies, including chimeric, humanized or fully human antibodies. The present invention is also directed to a method of reducing the severity of at least one symptom of an inflammatory bowel disease in a subject in need thereof comprising administering to said subject an effective amount of an antagonist of IP-10, including the antibodies or antibody fragments of the present invention.
1. An isolated anti-IP-10 antibody or antigen binding fragment which binds to the protein of SEQ ID NO: 1, wherein said antibody or antigen binding fragment comprises a heavy chain variable region comprising heavy chain complementarity determining regions (CDRs) of SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 74 and a light chain variable region comprising light chain CDRs of SEQ ID NO: 75, SEQ ID NO: 76, and SEQ ID NO: 77.
2. The isolated anti-IP-10 antibody or antigen binding fragment of claim 1 in which the heavy chain variable region comprises SEQ ID NO: 78.
3. The isolated anti-IP-10 antibody or antigen binding fragment of claim 1 in which the light chain variable region comprises SEQ ID NO: 46.
4. The isolated anti-IP-10 antibody or antigen binding fragment of claim 1 in which the heavy chain variable region comprises SEQ ID NO: 78 and the light chain variable region comprises SEQ ID NO: 46.
5. The isolated anti-IP-10 antibody according to claim 1 , wherein said antibody is monoclonal.
6. The isolated anti-IP-10 antibody according to claim 1 , wherein said antibody is a humanized antibody.
7. The isolated anti-IP-10 antibody according to claim 1 , wherein said antibody is a chimeric antibody.
8. A pharmaceutical composition comprising the isolated anti-IP-10 antibody or antigen binding fragment of claim 1 and a physiologically acceptable pharmaceutical carrier.
9. A method of treating or reducing severity of at least one symptom of an inflammatory bowel disease in a subject in need thereof, comprising administering to said subject an effective amount of an isolated anti-IP-10 antibody or antigen binding fragment of claim 1 , wherein said antibody or antigen binding fragment blocks the binding of CXCR3 to said SEQ ID NO: 1.
10. The method according to claim 9 , wherein said inflammatory bowel disease is Crohn's disease.
11. The method according to claim 9 , further comprising administering an immunosuppressive agent to the subject.
12. The method according to claim 9 , wherein said inflammatory bowel disease is ulcerative colitis.